Alterola Biotech Stock Total Asset
| ABTI Stock | USD 0 0.0001 2.44% |
Alterola Biotech fundamentals help investors to digest information that contributes to Alterola Biotech's financial success or failures. It also enables traders to predict the movement of Alterola Pink Sheet. The fundamental analysis module provides a way to measure Alterola Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alterola Biotech pink sheet.
Alterola |
Alterola Biotech Company Total Asset Analysis
Alterola Biotech's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Alterola Biotech Total Asset | 12.13 K |
Most of Alterola Biotech's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alterola Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Alterola Biotech has a Total Asset of 12.13 K. This is 100.0% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The total asset for all United States stocks is 100.0% higher than that of the company.
Alterola Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alterola Biotech's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Alterola Biotech could also be used in its relative valuation, which is a method of valuing Alterola Biotech by comparing valuation metrics of similar companies.Alterola Biotech is currently under evaluation in total asset category among its peers.
Alterola Fundamentals
| Return On Equity | -1.27 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 68.08 M | |||
| Shares Outstanding | 807.05 M | |||
| Price To Book | 6.29 X | |||
| EBITDA | (6.47 M) | |||
| Net Income | (6.47 M) | |||
| Cash And Equivalents | 61.54 K | |||
| Total Debt | 251.18 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 44.34 K | |||
| Earnings Per Share | (0.01) X | |||
| Beta | -6.65 | |||
| Market Capitalization | 39.55 M | |||
| Total Asset | 12.13 K | |||
| Net Asset | 12.13 K |
About Alterola Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alterola Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterola Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterola Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Alterola Pink Sheet
Alterola Biotech financial ratios help investors to determine whether Alterola Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterola with respect to the benefits of owning Alterola Biotech security.